People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aureon Biosciences, Inc. | — | Biotechnology | Series B | $51.3M | $668.2M | 2009 |
Carlos Cordon-Cardo, M.D., Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carlos Cordon-Cardo, M.D., Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Johnson | 1 | 12 |
| William Burkoth | 1 | 5 |
| Robert Van Nostrand | 1 | 2 |
| Robert Shovlin | 1 | 1 |
| Peter Barrett, Ph.D. | 1 | 1 |
| Philippe Chambon, M.D., Ph.D. | 1 | 1 |
| Jose Velasco, M.D. | 1 | 1 |
| Vijay Aggarwal, Ph.D. | 1 | 1 |
| Jose Costa, M.D. | 1 | 1 |
| Paul Veronese | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.